Can IBD patients safely stretch their infusion schedule? new study tests two strategies

NCT ID NCT03841942

Terminated Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at people with inflammatory bowel disease (Crohn's disease or ulcerative colitis) who are in deep remission. It compares two methods for gradually increasing the time between infliximab infusions: one based on symptoms and one based on drug levels in the blood. The goal is to see which approach better maintains remission and reduces the number of infusions needed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: infliximab
What this could lead to: If successful, this could allow some IBD patients to receive fewer infusions while maintaining remission, reducing treatment burden.
What could go wrong: This is a small, early-stage study. Spacing infusions may increase the risk of disease flare-ups or loss of remission.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATORY BOWEL DISEASES

Contacts and locations

Locations

APHP Beaujon Hospital

Paris, France
APHP Paris Cochin

Paris, France
Amiens University Hospital

Amiens, France
Besançon University Hospital

Besançon, France
Bordeaux University Hospital

Bordeaux, France
CHRU Nancy - Hôpitaux de Brabois

Nancy, France
Caen University Hospital

Caen, France
Clermont-Ferrand University Hospital

Clermont-Ferrand, France
Lille University Hospital

Lille, France
Nantes University Hospital

Nantes, France
Nice University Hospital

Nice, France
Nîmes University Hospital

Nîmes, France
Pineton de Chambrun

Montpellier, 34000, France
Rennes University Hospital

Rennes, France
Saint Etienne University Hospital

Saint-Etienne, France
Toulouse University Hospital

Toulouse, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.